若生智能
Drug Database
ME

meningococcal A conjugate vaccine (MenAfriVac)

✓ Approved

Serum Institute of India Pvt. Ltd. · 细胞治疗 · 细胞治疗

什么是 meningococcal A conjugate vaccine？

meningococcal A conjugate vaccine 是一种细胞治疗，由Serum Institute of India Pvt. Ltd.研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名MenAfriVac
公司Serum Institute of India Pvt. Ltd.
药物类别细胞治疗, 疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved
来源： ClinicalTrials.gov, Serum Institute of India Pvt. Ltd.

治疗适应症

meningococcal A conjugate vaccine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsMeningococcal bacteraemia✓ Approved

相关研究文献

PubMedVaccines2026-07-27

Improving Family Physicians' Vaccine Recommendation Behaviors for Non-Routine Vaccines (Meningococcal, Rotavirus, and HPV): A Two-Phase Intervention Study in Primary Care in Turkey.

Kilinç Özge Ö, Ünlü Ufuk U

In Turkey, meningococcal, rotavirus, and HPV vaccines are not included in the national schedule. We aimed to assess whether a face-to-face educational intervention could improve physicians' knowledge about these vaccines and influence their subsequent counseling and recommendation practices. We used a two-phase intervention with pre/post assessment and a 4-6-week follow-up among family physicians. In Phase 1, participants received an in-person structured educational intervention on meningococcal, rotavirus, and HPV vaccines, and their knowledge was evaluated using identical true/false tests administered before and after the session. Phase 2, conducted 4-6 weeks later, measured changes in physicians' self-reported frequency of providing recommendations about these vaccines, and whether they or their first-degree relatives had received any of the vaccines after the structured educational intervention. Differences in paired proportions were analyzed using McNemar's test (p < 0.05). Ninety-one physicians completed Phase-1; 70 from the same cohort completed Phase-2. Following the educational intervention, correct responses increased across multiple items: e.g., "Rotavirus vaccine is live" 89.0%→100% (p = 0.002); "Only humans are reservoir for meningococcal infection" 50.6%→96.7% (p < 0.001); "Meningococcal vaccine cannot be co-administered" (false) 70.3%→96.7% (p < 0.001). Phase-2 showed more proactive practice: for HPV, 52.9% reported recommending it "upon family request" and 27.1% "at every visit"; for rotavirus, these were 37.1% and 35.7%, respectively. Overall, 52.9% reported having administered one of the three vaccines to themselves or first-degree relatives after structured educational intervention; 62.2% rated the educational intervention's influence on that decision as 10/10. A structured educational intervention improved family physicians' knowledge and was associated with more proactive vaccine counseling and recommendation practices.

PMID 42506653
阅读全文 →
PubMedPaediatric drugs2026-07-27

21‑Valent Pneumococcal Conjugate Vaccine V116 (CAPVAXIVE®): Pediatric First Approval.

Shirley Matt M

The 21‑valent pneumococcal conjugate vaccine (PCV) V116 (CAPVAXIVE®), developed by Merck & Co., has been approved in the USA since June 2024 for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae in adults, with subsequent approvals in adults in the EU and a range of other countries. With the inclusion of eight S. pneumoniae serotypes that are not included in other currently licensed pneumococcal vaccines, V116 was designed to target residual pneumococcal disease in adults. Noting that some of the unique serotypes in V116 are responsible for significant pneumococcal disease in children and adolescents, the potential value of V116 in also complementing existing pediatric pneumococcal vaccination regimens has been explored. Supported by phase III clinical evaluation in children and adolescents with an increased risk of pneumococcal disease, in March 2026, V116 received its first pediatric approval, in the EU, for active immunization for the prevention of invasive disease and pneumonia caused by S. pneumoniae in children and adolescents 2 to < 18 years of age who previously completed a primary pediatric pneumococcal vaccination regimen. Subsequently, in June 2026, the US approval for V116 was extended to include use in individuals 2-17 years of age who are at increased risk for pneumococcal disease. This article summarizes the milestones in the development of V116 leading to these first pediatric approvals for active immunization for the prevention of invasive disease and pneumonia caused by S. pneumoniae.

PMID 42507077
阅读全文 →
PubMedVaccines2026-07-27

Economic Evaluations of New Vaccine Introduction in Middle-Income Countries in the Middle East and North Africa Region: A Systematic Review.

Bishop Chrissy C, Politopoulou Konstantina K, Bermudez Maria M, Rodriguez-Cairoli Federico F et al.

Middle-income countries (MICs) in the Middle East and North Africa (MENA) face financial and health system barriers when introducing new vaccines. The Gavi MICs approach has supported the introduction of pneumococcal conjugate (PCV), human papillomavirus (HPV), and rotavirus (RV) vaccines; however, economic evidence from the region remains limited. This systematic review assessed the quantity, characteristics, and quality of economic evaluations of these vaccines in MENA MICs published between 2015 and 2025 and synthesised economic evidence to inform policy decisions in Algeria, Egypt, Iran, Jordan, Lebanon, Morocco, Palestine, and Tunisia. Relevant databases and registries were searched for cost-effectiveness, cost-utility, cost-benefit, and budget impact analyses of PCV, HPV, and RV vaccination strategies. Two reviewers independently screened studies, extracted data, and assessed methodological quality. Twenty-six studies met the inclusion criteria, including 12 on HPV, nine on RV, and five on PCV. Vaccine introduction was the most commonly evaluated intervention (n = 23), and most studies were cost-effectiveness or cost-utility analyses adopting payer, health system, societal, or mixed perspectives. PCV and RV introduction were consistently found to be cost-effective or cost-saving. HPV introduction showed mixed results, particularly in Iran, but was generally cost-effective in Tunisia and Morocco. Reporting of vaccine coverage, delivery costs, and programmatic constraints was limited, and overall methodological quality varied. Available evidence supports the economic value of PCV and RV introduction in MENA MICs, while HPV's cost-effectiveness is context dependent. Future evaluations should incorporate dynamic modelling, implementation costs, and affordability considerations to better inform sustainable vaccine introduction.

PMID 42506628
阅读全文 →
PubMedVaccines2026-07-27

Untangling the Roots of HPV Vaccine Acceptance in West Virginia: How Hesitancy and Misinformation Shape Parental Decisions.

Guidry Jeanine P D JPD, Laestadius Linnea I LI, Engbersen-Severijns Yil Y, Miller Carrie A CA et al.

West Virginia is of particular concern regarding HPV vaccine hesitancy, currently ranking 45th among U.S. states in HPV vaccine uptake. General vaccine hesitancy and HPV- and HPV vaccine-specific misinformation, both associated with lower vaccination, have increased in recent years, complicating efforts to identify key drivers of HPV vaccine acceptance and effective intervention targets. This study used a Qualtrics survey of n = 330 parents of children aged 0-14 in West Virginia. Measures included parental HPV vaccine acceptance for their youngest child (reflecting either completed vaccination or intention to vaccinate), general vaccine hesitancy measured using the Vaccine Hesitancy Scale (VHS), and endorsement of nine common HPV- and HPV vaccine-specific misinformation statements. Misinformation items were summed and demonstrated good internal reliability (Cronbach's α = 0.868). Hierarchical logistic regression analyses indicated significant racial/ethnic differences across all model steps, with non-White parents less likely to report HPV vaccine acceptance for their child (p < 0.001). In Step 2, lower levels of general vaccine hesitancy predicted higher HPV vaccine acceptance (p < 0.001). In the final model, higher endorsement of HPV- and HPV vaccine-specific misinformation was associated with lower HPV vaccine acceptance (p = 0.035). These findings underscore the independent and additive influence of general vaccine hesitancy and HPV- and HPV vaccine-specific misinformation on parental HPV vaccine acceptance in West Virginia. Community-engaged public health strategies should prioritize strengthening vaccine confidence and directly addressing HPV- and HPV vaccine-specific misinformation, particularly among underserved populations.

PMID 42506645
阅读全文 →
PubMedVaccines2026-07-27

Human Papillomavirus Vaccine Intent and Associated Factors Among the Unvaccinated University Freshmen in the Largest University Town in China.

Yao Hongcen H, Lu Hongmei H, Zhu Qi Q, Shen Jinhua J et al.

Background: Human papillomavirus (HPV) vaccine has been proven a safe, necessary, and effective measure against HPV infection. However, HPV vaccine uptake remains limited among university students in China. This study investigated HPV vaccine intent among university freshmen in the largest university town in China. Methods: A cross-sectional online survey was conducted among unvaccinated female and male freshmen attending seven universities in Songjiang University Town, Shanghai, during 2024-2025. The questionnaire collected sociodemographic characteristics, HPV and HPV-vaccine-related knowledge, awareness, and vaccine intent. Factors associated with HPV vaccine intent were determined. Results: A total of 3397 valid questionnaires were collected, including female (60.02%) and male (39.98%) university freshmen. Overall, 76.12% were aware of HPV, 80.98% were aware of the HPV vaccine, and 84.31% expressed vaccine intent, with significantly higher rates among females than males (each p < 0.001). Socioeconomics, knowledge, awareness, sexual behavior, and HPV testing history were significantly associated with vaccine intent (each p < 0.05). The most common reason for no intent was perceived low risk of HPV-related diseases (40.53%). The most expected improvement measures were regulatory confirmation of vaccine safety and effectiveness (37.71%) and healthcare professionals' recommendations (37.71%), with no gender difference (each p > 0.05). Notably, 4.00% refused HPV vaccination, regardless of improvement measures. Additionally, most respondents preferred financial supporting policies, regardless of gender or vaccine intent (each p > 0.05). Conclusions: University freshmen showed the disparity between high awareness/intent and low knowledge. Financial considerations may influence HPV vaccination decisions. Thus, improving knowledge, particularly among males, and providing financial support may enhance HPV vaccine intent.

PMID 42506658
阅读全文 →
PubMedVaccines2026-07-27

Parental Vaccine Hesitancy in the Post-COVID-19 Era: Results from a Cross-Sectional Survey in the United States, 2025.

Duza Syeda Sharmin SS, Blackburn Christine Crudo CC, Rico Mayra M, Boyce Matthew R MR

Background/Objectives: Vaccine hesitancy has long been recognized to pose a significant barrier to achieving optimal immunization coverage and as a leading public health threat. However, much of the existing research on parental hesitancy toward routine childhood vaccines was conducted prior to the COVID-19 pandemic. Acknowledging the impact that this public health emergency had on attitudes toward vaccination, there is a need to conduct additional research into contemporary predictors of parental vaccine hesitancy. Methods: We conducted a survey in August 2025 to characterize vaccine hesitancy attitudes in parents in the United States. A series of 10 statements about vaccines was presented to study participants, who were asked to indicate their agreement with the statements using 5-point Likert scales. A vaccine hesitancy index measure was then calculated by averaging the scores, where higher scores corresponded to higher levels of vaccine hesitancy. A hierarchical regression analysis was then conducted to identify participant characteristics that were associated with vaccine hesitancy. Results: A total of 1016 individuals were included in the analysis. Simple linear regression suggested that education, annual household income, and politics were associated with vaccine hesitancy. The fully adjusted multiple linear regression model that accounted for participant demographic, socioeconomic, geographic, and political characteristics suggested significant associations between race, education, and partisanship. Conclusions: Significant associations exist between parental vaccine hesitancy and race, education, and partisanship. These results contribute to our understanding of vaccine hesitancy in a post-COVID-19 world and suggest that social, educational, and political factors meaningfully influence parental vaccine hesitancy in the United States.

PMID 42506638
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多meningococcal A conjugate vaccine